Discover results from the ODYSSEY OUTCOMES trial conducted in post-acute coronary syndrome (ACS) patients testing

View alirocumab dose titration and the ODYSSEY OUTCOMES
treat-to-target approach

Learn about primary MACE and additional CV endpoints in the overall population

Learn about the results on MACE in high risk patients (baseline LDL-C ≥100 mg/dL)

    ACS=acute coronary syndrome; LDL-C low-density lipoprotein cholesterol; MACE=major adverse cardiovascular events; PCSK9=proprotein convertase subtilisin/kexin type 9.